Financial News
Latest News about NBIX
Recent news which mentions NBIX
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
November 12, 2024
From Benzinga
Critical Insights From Neurocrine Biosciences Analyst Ratings: What You Need To Know
October 04, 2024
Tickers
NBIX
From Benzinga
"Rule Breaker Investing" Market Cap Game Show: Throwdowns & Long-Term Wins
September 30, 2024
From Motley Fool
Neurocrine Shifts Focus To New Schizophrenia Treatment After Luvadaxistat Trial Misses Endpoint
September 13, 2024
From Benzinga
Decoding 19 Analyst Evaluations For Neurocrine Biosciences
September 09, 2024
Tickers
NBIX
From Benzinga
Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio?
September 08, 2024
From Benzinga
Dollar General, Temu Parent PDD And Super Micro Computer Are Among Top 10 Large Cap Losers Last Week (Aug 25-Aug 31): Are The Others In Your Portfolio?
September 02, 2024
From Benzinga
Why Neurocrine Biosciences Stock Was Tumbling This Week
August 30, 2024
Tickers
NBIX
From Motley Fool
Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock
August 29, 2024
From Benzinga
From Benzinga
Nasdaq Down Over 1%; Foot Locker Shares Tumble After Q2 Results
August 28, 2024
From Benzinga
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
August 28, 2024
From Benzinga
US Stocks Mixed; JM Smucker Slashes Annual Guidance
August 28, 2024
From Benzinga
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
August 27, 2024
From Benzinga
9 Health Care Stocks Whale Activity In Today's Session
August 13, 2024
From Benzinga
From InvestorPlace
Tickers
NBIX
From InvestorPlace
3 Red-Hot Biotech Rockets Blasting Off in 2024
April 24, 2024
From InvestorPlace
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
April 23, 2024
From Benzinga
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
March 19, 2024
From Benzinga
From InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
